Pb-BCY20603 / Bicycle Therap, Orano - LARVOL DELTA

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle Radio-Conjugate Data at TIDES 2023 (Businesswire) - "Bicycle Therapeutics plc...announce pre-clinical results....The companies today announced co-authored preclinical results of Pb-BCY20603, a Bicycle® radio-conjugate (BRC™) that binds with high affinity to the tumor antigen MT1-MMP and carries a chelate of lead-212, a potent alpha particle emitting radioisotope. The results were presented at TIDES 2023 in San Diego, CA and can be accessed here....Pb-BCY20603 showed tumor targeting in rodent tumor xenograft studies, with radioactivity levels of >45% Injected Dose (ID/g) 24 hours post injection....Pb-BCY20603 showed potent anti-tumor activity after a single dose of 5 μCi. Complete tumor regressions were seen after 3 dosing cycles of 10 μCi, given two weeks apart. Median survival was increased for each dosing group with 90% survival observed for the 3 cycles of 10 μCi, treatment at the end of the 100-day study."

Preclinical • Oncology